Press

Newsroom

ImpriMed Raises $23 Million Series A Round to Expand its Revolutionary AI-Powered Cancer Treatment Technology

Business Wire
Learn More →

ImpriMed Celebrates the Milestone of 4,000 Dog Blood Cancer Patients

Business Insider
Learn More →

ImpriMed Wins Place at the Mayo Clinic Platform_Accelerate Immersive Program

EIN Presswire
Learn More →

40 Under 40 in Cancer Class of 2022 Recognizes Dr. Sungwon Lim, ImpriMed CEO & Co-Founder

EIN Presswire
Learn More →

ImpriMed Presents New Research Findings at The Veterinary Cancer Society (VCS) Mid-Year Conference

EIN Presswire
Learn More →

ImpriMed AI and machine learning is disrupting the veterinary oncology tools available for better treatment outcomes

EIN Presswire
Learn More →

ImpriMed Publishes Exclusive Canine Patients Data Analysis

EIN Presswire
Learn More →

ImpriMed CEO and Co-founder Dr. Sungwon Lim Wins Prestigious “Top Industry Leader” Award from Life Sciences Voice

EIN Presswire
Learn More →

ImpriMed Reports Significant Growth in 2021 with Pre-Series A Funding, New Product Launches, and Team Expansion

EIN Presswire
Learn More →

ImpriMed Launches New Diagnostic Services for Canine Lymphoma

EIN Presswire
Learn More →

ImpriMed Initiates Feline Lymphoma Drug Response Prediction Study

EIN Presswire
Learn More →

ImpriMed Launches Chemo Response Prediction and Immunophenotyping Services for Canine Lymphoma

GlobeNewswire
Learn More →

ImpriMed Raises $8M to Commercialize AI-Driven Personalized Drug Response Prediction Service in Pet Cancer Market

GlobeNewswire
Learn More →

ImpriMed Launches Advanced Precision Medicine Service for Canine Blood Cancers

PR Underground
Learn More →

ImpriMed Raises $4M for Customized Cancer Treatments for Dogs

GlobeNewswire
Learn More →